Scientists are exploring a new gene editing approach that could offer a one-time treatment for preventing heart disease. This innovative method aims to provide a durable solution for conditions like hypercholesterolemia, a major risk factor for cardiovascular issues.
Pharmaceutical company Eli Lilly announced promising results from its VERVE-102 base editor. A single dose of VERVE-102 reduced PCSK9 levels by up to 88% and LDL-C (bad cholesterol) by up to 62%. These effects were sustained, suggesting the treatment could be comparable to existing PCSK9 inhibitors.
The findings indicate a significant step toward a potential "one-and-done" therapy for high cholesterol, which could revolutionize heart disease prevention. This is a developing story and will be updated as details emerge.
